Checkpoint Therapeutics Inc (CKPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Checkpoint Therapeutics Inc (CKPT) has a cash flow conversion efficiency ratio of -0.717x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.69 Million) by net assets ($16.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CKPT net asset quality score to measure how much of total assets are equity-financed.
Checkpoint Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Checkpoint Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CKPT total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Checkpoint Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Checkpoint Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Monro Muffler Brake Inc
NASDAQ:MNRO
|
0.029x |
|
Regulus Resources Inc
V:REG
|
-0.007x |
|
Van de Velde NV
BR:VAN
|
0.127x |
|
ROUTE MOBILE LIMITED
NSE:ROUTE
|
0.015x |
|
Ashoka Buildcon Limited
NSE:ASHOKA
|
0.099x |
|
Hiyes International Co Ltd
TW:2348
|
0.010x |
|
Viva Wine Group AB
ST:VIVA
|
0.014x |
|
Guangdong Zhengye Technology Co Ltd
SHE:300410
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Checkpoint Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Checkpoint Therapeutics Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Checkpoint Therapeutics Inc (CKPT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.62 Million | $-31.10 Million | 2.463x | -32.46% |
| 2023-12-31 | $-13.05 Million | $-47.59 Million | 3.648x | +23.48% |
| 2022-12-31 | $-19.48 Million | $-57.55 Million | 2.954x | +434.04% |
| 2021-12-31 | $29.75 Million | $-26.31 Million | -0.884x | -89.04% |
| 2020-12-31 | $35.38 Million | $-16.55 Million | -0.468x | +58.75% |
| 2019-12-31 | $18.85 Million | $-21.37 Million | -1.134x | +48.12% |
| 2018-12-31 | $11.81 Million | $-25.80 Million | -2.186x | -112.64% |
| 2017-12-31 | $15.04 Million | $-15.46 Million | -1.028x | -233.74% |
| 2016-12-31 | $32.30 Million | $-9.95 Million | -0.308x | -1189.72% |
| 2015-12-31 | $46.40 Million | $-1.11 Million | -0.024x | -- |
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more